United Kingdom Hyperhidrosis Market Insight
Published: 29 July 2026 | Report Format: Electronic (PDF) | Author: Sanket and Pranali
The United Kingdom Hyperhidrosis Market was valued at USD 0.21 Billion in 2025 and is projected to reach USD 0.39 Billion by 2035, expanding at a CAGR of 6.39% during the forecast period. Market growth is being supported by the increasing prevalence of primary hyperhidrosis, rising awareness of dermatological disorders, greater adoption of minimally invasive treatment options such as botulinum toxin injections and microwave therapy, expanding access to specialist dermatology clinics, and continuous advancements in prescription topical therapies and medical devices for excessive sweating management.
United Kingdom Hyperhidrosis Market Forecasts to 2035
- The United Kingdom Hyperhidrosis Market was estimated at USD 0.21 Billion in 2025.
- The market is expected to grow at a CAGR of 6.39% from 2025 to 2035.
- The market is projected to reach approximately USD 0.39 Billion by 2035.
Notable Insights for the United Kingdom Hyperhidrosis Market
- Segmentation Based on Treatment Type, Botulinum Toxin Therapy accounted for the largest market share of approximately 44.8% in 2025, supported by strong clinical efficacy, long-lasting sweat reduction, and increasing patient preference for minimally invasive outpatient procedures.
- Segmentation Based on End User, Hospitals & Dermatology Clinics represented nearly 58.6% of total market revenue in 2025, driven by growing referrals to specialist dermatologists, wider availability of advanced treatment options, and increasing diagnosis of chronic hyperhidrosis cases.
- AbbVie Inc. reported USD 56.33 Billion in revenue during fiscal 2025, supported by its expanding neuroscience and aesthetics portfolio, including Botox therapies widely used for managing severe primary axillary hyperhidrosis across global healthcare markets.
- Dermata Therapeutics, Inc. generated approximately USD 12.8 Million in revenue during fiscal 2025, reflecting continued commercialization efforts, expanding dermatology treatment programs, and ongoing innovation in topical therapies targeting chronic skin conditions, including excessive sweating disorders.
Download the eBook (ToC)
Research Methodologies Used to Analyze the United Kingdom Hyperhidrosis Market
This study combines primary and secondary research methodologies to evaluate the United Kingdom Hyperhidrosis Market. Primary research includes interviews with dermatologists, plastic surgeons, pharmaceutical manufacturers, medical device suppliers, hospital procurement managers, healthcare distributors, regulatory specialists, clinical researchers, and senior industry executives. Secondary research incorporates company annual reports, NHS publications, MHRA guidelines, dermatology journals, clinical trial databases, industry associations, white papers, healthcare statistics, and commercial market intelligence sources. Market estimates are developed using both top-down and bottom-up approaches, while data triangulation ensures reliable market sizing, competitive benchmarking, and long-term forecasting accuracy.
Decisions Advisors Research Methodology: Trusted Insights for Strategic Decision-Making
What is Decisions Advisors Research?
Decisions Advisors research delivers comprehensive market intelligence through detailed industry analysis, competitive benchmarking, trend forecasting, and data-driven business insights. Our research methodology combines advanced analytical frameworks with extensive primary and secondary research to help organizations make informed and strategic business decisions.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Hyperhidrosis Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Hyperhidrosis Market
- AbbVie Inc.
- Dermata Therapeutics, Inc.
- Candesant Biomedical
- Journey Medical Corporation
- Dr. August Wolff GmbH & Co. KG Arzneimittel
- Merz Pharma GmbH & Co. KGaA
- Revance Therapeutics, Inc.
- Miramar Labs, Inc.
- Dermadry Laboratories Inc.
- Hidrex GmbH.
Recent Developments:
- In October 2025, AbbVie Inc. expanded the clinical positioning of BOTOX® for hyperhidrosis management through updated physician education programs and enhanced treatment support initiatives across dermatology clinics in the United Kingdom.
- In June 2025, Candesant Biomedical collaborated with leading United Kingdom dermatology specialists to broaden the clinical evaluation of its Sweanty™ topical hyperhidrosis treatment, supporting improved patient access and real-world therapeutic assessment.
Market Segmentation
United Kingdom Hyperhidrosis Market, By Treatment Type
- Botulinum Toxin Therapy
- Topical Medications
- Oral Medications
- Iontophoresis
- Microwave Therapy
- Surgical Treatment
United Kingdom Hyperhidrosis Market, By Hyperhidrosis Type
- Primary Hyperhidrosis
- Secondary Hyperhidrosis
United Kingdom Hyperhidrosis Market, By End User
- Hospitals & Dermatology Clinics
- Ambulatory Surgical Centers
- Specialty Clinics
- Home Care Settings
United Kingdom Hyperhidrosis Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
United Kingdom Hyperhidrosis Market, By Region
- England
- Scotland
- Wales
- Northern Ireland
Expert Views:
The United Kingdom Hyperhidrosis Market is expected to witness steady growth through 2035 as awareness of excessive sweating disorders continues to improve and access to specialist dermatology care expands. Increasing demand for minimally invasive therapies, innovative topical formulations, and advanced medical devices is encouraging manufacturers to strengthen product portfolios through continuous innovation and strategic collaborations, supporting better patient outcomes and long-term market expansion.
Author: Sanket and Pranali By Decisions Advisors and Consulting